DALIVIT price in UAE

Overview

Welcome to Dwaey, specifically on DALIVIT Drops (Oral) page.
This medicine contains an important and useful components, as it consists of Vitamin - A / B1 / B2 / B6 / Nicotinamide / C / D.
DALIVIT is available in the market in concentration Combination and in the form of Drops (Oral).

PAINES & BYRNE LlMITED is the producer of DALIVIT and it is imported from UK, The most popular alternatives of DALIVIT are listed downward .

Mode Of Action

Almotriptan is a selective serotonin agonist which acts mainly on the 5-HT1 receptors and produces cranial vasodilation. It is used for the acute treatment of migraine.

Indication

Migraine headache
Acute migraine attacks

Precaution

Hypersensitivity to sulfonamides. Hepatic or moderate-severe renal impairment. Caution when used in patients with a history of seizures. May significantly increase BP. May cause drowsiness. Children <18 yr. Pregnancy, lactation. Lactation: excretion in milk unknown; use with caution

Side Effects

1-10% Somnolence (1-5%)
Dizziness (3-4%)
Nausea (1-3%)
Vomiting (2%)
Dry mouth (1-2%)
Headache (1-2%)
Nausea (1-2%)
Paresthesia (1-2%)
Paresthesia (1%)
Somnolence (>1%) <1% Infrequent (0.01-0.001%) Anxiety
asthenia
chills
CNS stimulation
fatigue
hypesthesia
tremor
Pruitus
rash
Diaphoresis
dysmenorrhea
hyperglycemia
increased thirst
Abdominal cramp
gastroenteritis Back pain
myalgia
neck pain
rigid neck
Increased CPK
Bronchitis
chest pain
dyspnea
pharyngitis
rhinitis
sinusitis
Conjunctivitis
tinnitis
vertigo Potentially Fatal: Serious cardiac events.

Contra indication

Underlying CV disease e.g. ischaemic heart disease or coronary artery vasospasm. Uncontrolled hypertension. Severe hepatic or renal impairment. Prophylaxis of migraine, hemiplegic or basilar migraine; cluster headache. Use within 24 hr of another 5-HT1 agonist; use within 24 hr of ergotamine derivative; concurrent use or within 2 wk of discontinuing an MAOI.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Increased risk of serotonin syndrome when used with SSRIs or serotonin norepinephrine reuptake inhibitors. Increased plasma concentrations when used with verapamil, ketoconazole or other potent CYP450 inhibitors. Potentially Fatal: Severe vasospastic reactions may occur when given within 24 hr of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-like medication. Avoid usage with or within 2 wk of stopping treatment with a MAOI.